The status of live viral vaccination in early life

Vaccine

Volumn 31, Issue 21, 2013, Pages 2531-2537

  Gans, Hayley A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Infant vaccination; Live viral vaccine

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; MEASLES VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE;

CHICKENPOX; CHILD HEALTH CARE; CHILDHOOD MORTALITY; DISEASE SEVERITY; HUMAN; IMMUNE SYSTEM; INCIDENCE; INFLUENZA; MEASLES; MUMPS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; ROTAVIRUS; RUBELLA; VACCINATION;

HUMANS; INFANT; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS DISEASES;

EID: 84877803243     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.043     Document Type: Review

References (99)

1. WHO World Health Statistics 2011, W. Press (Ed.).
2. MMWR Vaccine-preventable diseases, immunizations, and MMWR-1961-2011. MMWR Morb Mortal Wkly Rep 2011, 60:49-57.
3. Daniels D., Jiles R.B., Klevens R.M., Herrera G.A. Undervaccinated African-American preschoolers: a case of missed opportunities. Am J Prev Med 2001, 20:61-68.
4. Menzies R., Turnour C., Chiu C., McIntyre P. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006. Commun Dis Intell 2008, 32(Suppl.):S2-S67.
5. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
6. Groothuis J.R., Hoopes J.M., Jessie V.G. Prevention of serious respiratory syncytial virus-related illness. I. Disease pathogenesis and early attempts at prevention. Adv Ther 2011, 28:91-109.
7. Nair H., Brooks W.A., Katz M., Roca A., Berkley J.A., Madhi S.A., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011, 378:1917-1930.
8. Parashar U.D., Burton A., Lanata C., Boschi-Pinto C., Shibuya K., Steele D., et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009, 200(Suppl. 1):S9-S15.
9. Glass R.I., Kilgore P.E., Holman R.C., Jin S., Smith J.C., Woods P.A., et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis 1996, 174(Suppl. 1):S5-S11.
10. Kilgore P.E., Holman R.C., Clarke M.J., Glass R.I. Trends of diarrheal disease-associated mortality in US children, 1968 through 1991. JAMA 1995, 274:1143-1148.
11. MMWR Prevention of rotavirus gastroenteritis among infants and children recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2009, 58:1-25.
12. MMWR Rotavirus vaccines: an update. MMWR Wkly Epidemiol Rec 2009, 84:533-540.
13. MMWR Rotavirus surveillance-worldwide, 2009. MMWR Morb Mortal Wkly Rep 2010, 60:514-516.
14. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
15. Tate J.E., Parashar U.D. Monitoring impact and effectiveness of rotavirus vaccination. Expert Rev Vaccines 2011, 10:1123-1125.
16. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
17. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:606-614.
18. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
19. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623.
20. CDC Global measles mortality, 2000-2008. MMWR 2009, 58:1321-1326.
21. Aaby P., Andersen M., Sodemann M., Jakobsen M., Gomes J., Fernandes M. Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age. BMJ 1993, 307:1308-1311.
22. CDC Progress in reducing global measles deaths, 1999-2004. MMWR 2006, 55:247-249.
23. Zarocostas J. Mortality from measles fell by 91% in Africa from 2000 to 2006. BMJ 2007, 335:1173.
24. CDC Update: Measles-United States, January-July 2008. MMWR 2008, 57:893-896.
25. Gans H., Arvin A., Galinus J., Logan L., DeHovitz R., Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998, 280:527-532.
26. Gans H, Yasukawa L, Alderson A, Rinki M, DeHovitz R, Maldonado Y, Beeler J, Audet S, Arvin AM. Humoral and cell-mediated immune responses to an early two-dose measles vaccination regimen in the United States. J Infect Dis 2004; 189.
27. Kumar M.L., Johnson C.E., Chui L.W., Whitwell J.K., Staehle B., Nalin D. Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers [published erratum appears in Vaccine 1999 Apr 23;17(17):2206]. Vaccine 1998, 16:2047-2051.
28. Maldonado Y.A., Lawrence E.C., DeHovitz R., Hartzell H., Albrecht P. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics 1995, 96:447-450.
29. Markowitz L.E., Albrecht P., Rhodes P., Demonteverde R., Swint E., Maes E.F., et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Pediatrics 1996, 97:53-58.
30. Carson M.M., Spady D.W., Albrecht P., Beeler J.A., Thipphawong J., Barreto L., et al. Measles vaccination of infants in a well-vaccinated population. Pediatr Infect Dis J 1995, 14:17-22.
31. Leuridan E., Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine 2007, 25:6296-6304.
32. Dayan G.H., Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?. Clin Infect Dis 2008, 47:1458-1467.
33. Khandaker G., Marshall H., Peadon E., Zurynski Y., Burgner D., Buttery J., et al. Congenital and neonatal varicella: impact of the national varicella vaccination programme in Australia. Arch Dis Child 2011, 96:453-456.
34. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915.
35. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007, (204):1405-1416.
36. Pulendran B., Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006, 124:849-863.
37. Zhu J., Martinez J., Huang X., Yang Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 2007, 109:619-625.
38. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, 9:1131-1137.
39. Carson M.M., Spady D.W., Beeler J.A., Krezolek M.P., Audet S., Pabst H.F. Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII at 15 months of age and antibody levels at 27 months of age. Vaccine 2005, 23:3247-3255.
40. Ward B.J., Boulianne N., Ratnam S., Guiot M.C., Couillard M., De Serres G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995, 172:1591-1595.
41. Permar S.R., Klumpp S.A., Mansfield K.G., Carville A.A., Gorgone D.A., Lifton M.A., et al. Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J Infect Dis 2004, 190:998-1005.
42. Aaby P., Bukh J., Leerhoy J., Lisse I.M., Mordhorst C.H., Pedersen I.R. Vaccinated children get milder measles infection: a community study from Guinea-Bissau. J Infect Dis 1986, 154:858-863.
43. Gans H., DeHovitz R., Forghani B., Beeler J., Maldonado Y., Arvin A.M. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 2003, 21:3398-3405.
44. Gans H.A., Arvin A.M., Galinus J., Logan L., DeHovitz R., Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998, 280:527-532.
45. Moon S.S., Wang Y., Shane A.L., Nguyen T., Ray P., Dennehy P., et al. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J 2010, 29:919-923.
46. Gans H.A., Yasukawa L.L., Alderson A., Rinki M., DeHovitz R., Beeler J., et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 2004, 190:83-90.
47. Nair N., Gans H., Lew-Yasukawa L., Long-Wagar A.C., Arvin A., Griffin D.E. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 2007, 196:1339-1345.
48. Jelonek M.T., Maskrey J.L., Steimer K.S., Potts B.J., Higgins K.W., Keller M.A. Maternal monoclonal antibody to the V3 loop alters specificity of the response to a human immunodeficiency virus vaccine. J Infect Dis 1996, 174:866-869.
49. Panpitpat C., Thisyakorn U., Chotpitayasunondh T., Furer E., Que J.U., Hasler T., et al. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine. Bull World Health Organ 2000, 78:364-371.
50. Siegrist C., Barrios C., Martinex X., Brandt C., Cordova M., Kovarik J., et al. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur J Immunol 1998, 28:4138-4148.
51. Weeratna R.D., Brazolot Millan C.L., McCluskie M.J., Siegrist C.A., Davis H.L. Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. FEMS Immunol Med Microbiol 2001, 30:241-247.
52. Kim D., Huey D., Oglesbee M., Niewiesk S. Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood 2011, 117:6143-6151.
53. Johnson C.E., Nalin D.R., Chui L.W., Whitwell J., Marusyk R.G., Kumar M.L. Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era. Pediatrics 1994, 93:939-944.
54. Markowitz L.E., Sepulveda J., Diaz-Ortega J.L., Valdespino J.L., Albrecht P., Zell E.R., et al. Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines [published erratum appears in N Engl J Med 1990 Mar 22;322(12):863]. N Engl J Med 1990, 322:580-587.
55. Ndumbe P.M., Gilchrist S.A., Pabst H., Sama M.T., Mbede J. Comparison of Edmonston-Zagreb, Connaught and Schwarz measles vaccines in Cameroonian infants aged 3-8 months. Vaccine 1995, 13:276-280.
56. Tidjani O., Grunitsky B., Guerin N., Levy-Bruhl D., Lecam N., Xuereff C., et al. Serological effects of Edmonston-Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months. Lancet 1989, 2:1357-1360.
57. Gans H., Yasukawa L., Rinki M., DeHovitz R., Forghani B., Beeler J., et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001, 184:817-826.
58. Linnemann C.C., Dine M.S., Roselle G.A., Askey P.A. Measles immunity after revaccination: results in children vaccinated before 10 months of age. Pediatrics 1982, 69:332-335.
59. Hutchins S.S., Dezayas A., Le Blond K., Heath J., Bellini W., Audet S., et al. Evaluation of an early two-dose measles vaccination schedule. Am J Epidemiol 2001, 154:1064-1071.
60. Stetler H.C., Orenstein W.A., Bernier R.H., Herrmann K.L., Sirotkin B., Hopfensperger D., et al. Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics 1986, 77:471-476.
61. Aaby P., Samb B., Simondon F., Seck A.M., Knudsen K., Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ 1995, 311:481-485.
62. Ceyhan M., Kanra G., Erdem G., Kanra B. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine 2001, 19:4473-4478.
63. Garly M.L., Bale C., Martins C.L., Monteiro M., George E., Kidd M., et al. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. Vaccine 2001, 19:1951-1959.
64. John S., Lalitha G., George K., Joseph A. Serological response to early measles vaccination. J Trop Pediatr 2004, 50:175-177.
65. Gans H.A., Maldonado Y., Yasukawa L.L., Beeler J., Audet S., Rinki M.M., et al. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol 1999, 162:5569-5575.
66. Wong-Chew R.M., Islas-Romero R., Garcia-Garcia Mde L., Beeler J.A., Audet S., Santos-Preciado J.I., et al. Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. J Infect Dis 2004, 189:254-257.
67. Wong-Chew R.M., Islas-Romero R., Garcia-Garcia Mde L., Beeler J.A., Audet S., Santos-Preciado J.I., et al. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine 2006, 24:683-690.
68. Wong-Chew R.M., Garcia-Leon M.L., Espinosa-Torres Torrija B., Hernandez-Perez B., Cardiel-Marmolejo L.E., Beeler J.A., et al. Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously. J Infect Dis 2011, 204:426-432.
69. Bellanti J.A., Zeligs B.J., Mendez-Inocencio J., Garcia-Garcia M.L., Islas-Romero R., Omidvar B., et al. Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine. Vaccine 2004, 22:1214-1220.
70. Gray J. Rotavirus vaccines: safety, efficacy and public health impact. J Intern Med 2011, 270:206-214.
71. Vesikari T., Karvonen A., Ferrante S.A., Kuter B.J., Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J 2010, 29:957-963.
72. Ward R. Mechanisms of protection against rotavirus infection and disease. Pediatr Infect Dis J 2009, 28:S57-S59.
73. Glass R.I., Bhan M.K., Ray P., Bahl R., Parashar U.D., Greenberg H., et al. Development of candidate rotavirus vaccines derived from neonatal strains in India. J Infect Dis 2005, 192(Suppl. 1):S30-S35.
74. Offit P.A., Hoffenberg E.J., Pia E.S., Panackal P.A., Hill N.L. Rotavirus-specific helper T cell responses in newborns, infants, children, and adults. J Infect Dis 1992, 165:1107-1111.
75. Dennehy P.H., Vesikari T., Matson D.O., Itzler R.F., Dallas M.J., Goveia M.G., et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R) (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccin 2011, 7:563-568.
76. Vesikari T., Karvonen A., Forrest B.D., Hoshino Y., Chanock R.M., Kapikian A.Z. Neonatal administration of rhesus rotavirus tetravalent vaccine. Pediatr Infect Dis J 2006, 25:118-122.
77. Bishop R.F., Barnes G.L., Cipriani E., Lund J.S. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983, 309:72-76.
78. el-Madhun A.S., Cox R.J., Soreide A., Olofsson J., Haaheim L.R. Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J Infect Dis 1998, 178:933-939.
79. Johnson P.R., Feldman S., Thompson J.M., Mahoney J.D., Wright P.F. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol 1985, 17:325-335.
80. Goveia M.G., DiNubile M.J., Dallas M.J., Heaton P.M., Kuter B.J. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr Infect Dis J 2008, 27:656-658.
81. Rennels M.B. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J Infect Dis 1996, 174(Suppl. 1):S107-S111.
82. Chan J., Nirwati H., Triasih R., Bogdanovic-Sakran N., Soenarto Y., Hakimi M., et al. Maternal antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countries?. Vaccine 2011, 29:1242-1247.
83. Steele A.D., De Vos B., Tumbo J., Reynders J., Scholtz F., Bos P., et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2010, 28:6542-6548.
84. Patel M., Shane A.L., Parashar U.D., Jiang B., Gentsch J.R., Glass R.I. Oral rotavirus vaccines: how well will they work where they are needed most?. J Infect Dis 2009, 200(Suppl. 1):S39-S48.
85. Aggarwal R., Sentz J., Miller M.A. Role of zinc administration in prevention of childhood diarrhea and respiratory illnesses: a meta-analysis. Pediatrics 2007, 119:1120-1130.
86. Grassly N.C., Jafari H., Bahl S., Durrani S., Wenger J., Sutter R.W., et al. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis 2009, 200:794-801.
87. Ing D.J., Glass R.I., Woods P.A., Simonetti M., Pallansch M.A., Wilcox W.D., et al. Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine. Am J Dis Child 1991, 145:892-897.
88. Myaux J.A., Unicomb L., Besser R.E., Modlin J.F., Uzma A., Islam A.M., et al. Effect of diarrhea on the humoral response to oral polio vaccination. Pediatr Infect Dis J 1996, 15:204-209.
89. Posey D.L., Linkins R.W., Oliveria M.J., Monteiro D., Patriarca P.A. The effect of diarrhea on oral poliovirus vaccine failure in Brazil. J Infect Dis 1997, 175(Suppl. 1):S258-S263.
90. Ota M.O., Vekemans J., Schlegel-Haueter S.E., Fielding K., Sanneh M., Kidd M., et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002, 168:919-925.
91. Rhorer J., Ambrose C.S., Dickinson S., Hamilton H., Oleka N.A., Malinoski F.J., et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009, 27:1101-1110.
92. Fleming D.M., Crovari P., Wahn U., Klemola T., Schlesinger Y., Langussis A., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006, 25:860-869.
93. Negri E., Colombo C., Giordano L., Groth N., Apolone G., La Vecchia C. Influenza vaccine in healthy children: a meta-analysis. Vaccine 2005, 23:2851-2861.
94. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R., Chotpitayasunondh T., Tam J.S., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
95. Vesikari T., Fleming D.M., Aristegui J.F., Vertruyen A., Ashkenazi S., Rappaport R., et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006, 118:2298-2312.
96. Belshe R.B., Gruber W.C., Mendelman P.M., Cho I., Reisinger K., Block S.L., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000, 136:168-175.
97. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181:1133-1137.
98. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
99. Wright P.F., Karron R.A., Belshe R.B., Thompson J., Crowe J.E., Boyce T.G., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000, 182:1331-1342.